{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:56Z","timestamp":1793730956568,"version":"4.6.1"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200713"],"award-info":[{"award-number":["82200713"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115717","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T14:34:20Z","timestamp":1697639660000},"page":"115717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Advances in targeted therapy for pancreatic cancer"],"prefix":"10.1016","volume":"168","author":[{"given":"Lin","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinya","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3266-4314","authenticated-orcid":false,"given":"Deshi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2023.115717_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med J. (Engl. )"},{"issue":"10","key":"10.1016\/j.biopha.2023.115717_bib2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/00365521.2022.2067786","article-title":"Pancreatic cancer - the past, the present, and the future","volume":"57","author":"Andersson","year":"2022","journal-title":"Scand. J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115717_bib3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2023.115717_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"18","key":"10.1016\/j.biopha.2023.115717_bib5","doi-asserted-by":"crossref","first-page":"7635","DOI":"10.18632\/aging.204310","article-title":"A comprehensive review of pancreatic cancer and its therapeutic challenges","volume":"14","author":"Jiang","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"18","key":"10.1016\/j.biopha.2023.115717_bib6","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.7150\/thno.60350","article-title":"Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma","volume":"11","author":"Mashayekhi","year":"2021","journal-title":"Theranostics"},{"issue":"19","key":"10.1016\/j.biopha.2023.115717_bib7","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","article-title":"Challenges in diagnosis of pancreatic cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115717_bib8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115717_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/SLA.0b013e3181613142","article-title":"Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?","volume":"247","author":"Schnelldorfer","year":"2008","journal-title":"Ann. Surg."},{"issue":"10","key":"10.1016\/j.biopha.2023.115717_bib10","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/biom11101469","article-title":"Recent advances in pancreatic cancer: novel prognostic biomarkers and targeted therapy-a review of the literature","volume":"11","author":"Schick","year":"2021","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.biopha.2023.115717_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib12","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"18","key":"10.1016\/j.biopha.2023.115717_bib13","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.7150\/thno.60350","article-title":"Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma","volume":"11","author":"Mashayekhi","year":"2021","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.biopha.2023.115717_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.18773\/austprescr.2015.060","article-title":"Oral targeted therapy for cancer","volume":"38","author":"Carrington","year":"2015","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.biopha.2023.115717_bib15","article-title":"BUB1 is identified as a potential therapeutic target for pancreatic cancer treatment","volume":"10","author":"Li","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.biopha.2023.115717_bib16","doi-asserted-by":"crossref","first-page":"1610694","DOI":"10.3389\/pore.2022.1610694","article-title":"On-target side effects of targeted therapeutics of cancer","volume":"28","author":"T\u00edm\u00e1r","year":"2022","journal-title":"Pathol. Oncol. Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.36401\/JIPO-20-21","article-title":"Targeted cancer therapy and its ophthalmic side effects: a review","volume":"4","author":"Bindiganavile","year":"2021","journal-title":"J. Immunother. Precis Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the design of antibody-based therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"20","key":"10.1016\/j.biopha.2023.115717_bib19","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2023.115717_bib21","article-title":"A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer","volume":"11","author":"Jin","year":"2021","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115717_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrd2530","article-title":"Drug development of MET inhibitors: targeting oncogene addiction and expedience","volume":"7","author":"Comoglio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.biopha.2023.115717_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"24","key":"10.1016\/j.biopha.2023.115717_bib24","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.3748\/wjg.v12.i24.3878","article-title":"Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer","volume":"12","author":"Yu","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"22","key":"10.1016\/j.biopha.2023.115717_bib25","first-page":"5775","article-title":"Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer","volume":"54","author":"Ebert","year":"1994","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.biopha.2023.115717_bib26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41401-018-0198-0","article-title":"SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models","volume":"40","author":"Yang","year":"2019","journal-title":"Acta Pharm. Sin."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12935-022-02839-w","article-title":"Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model","volume":"22","author":"Wu","year":"2022","journal-title":"Cancer Cell Int"},{"issue":"47","key":"10.1016\/j.biopha.2023.115717_bib28","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1038\/onc.2011.651","article-title":"MUC1 regulates PDGFA expression during pancreatic cancer progression","volume":"31","author":"Sahraei","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2023.115717_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.670396","article-title":"Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study","volume":"11","author":"Striefler","year":"2021","journal-title":"Front Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115717_bib30","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/ijms19072004","article-title":"A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model","volume":"19","author":"Wu","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib31","doi-asserted-by":"crossref","first-page":"1699768","DOI":"10.1080\/19420862.2019.1699768","article-title":"Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies","volume":"12","author":"Li","year":"2020","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib32","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.biopha.2023.115717_bib33","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/jcm10061332","article-title":"Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)","volume":"10","author":"Chang","year":"2021","journal-title":"J. Clin. Med"},{"issue":"10","key":"10.1016\/j.biopha.2023.115717_bib34","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3390\/pharmaceutics14102131","article-title":"Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy","volume":"14","author":"Cho","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.biopha.2023.115717_bib35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2023.115717_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1756287220980192","article-title":"Enfortumab Vedotin in urothelial cancer","volume":"12","author":"Alt","year":"2020","journal-title":"Ther. Adv. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115717_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/1878-0261.12400","article-title":"An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies","volume":"13","author":"Hu","year":"2019","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115717_bib38","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","article-title":"Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen","volume":"66","author":"Kovtun","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2023.115717_bib39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1172\/JCI200113712","article-title":"Glypicans: proteoglycans with a surprise","volume":"108","author":"Filmus","year":"2001","journal-title":"J. Clin. Invest"},{"issue":"14","key":"10.1016\/j.biopha.2023.115717_bib40","first-page":"5562","article-title":"Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells","volume":"61","author":"Matsuda","year":"2001","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2023.115717_bib41","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1172\/JCI4105","article-title":"The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer","volume":"102","author":"Kleeff","year":"1998","journal-title":"J. Clin. Invest"},{"issue":"9","key":"10.1016\/j.biopha.2023.115717_bib42","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-020-0781-2","article-title":"Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer","volume":"122","author":"Nishigaki","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.115717_bib43","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ijc.31124","article-title":"Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer","volume":"142","author":"Matsuzaki","year":"2018","journal-title":"Int J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.115717_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations","volume":"10","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.biopha.2023.115717_bib45","first-page":"43","article-title":"Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery","volume":"8","author":"Kim","year":"2021","journal-title":"Bioeng. (Basel)"},{"issue":"8","key":"10.1016\/j.biopha.2023.115717_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160890","article-title":"Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics","volume":"11","author":"Waight","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark. Res"},{"issue":"6","key":"10.1016\/j.biopha.2023.115717_bib48","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.addr.2005.01.006","article-title":"Role of claudins in tumorigenesis","volume":"57","author":"Swisshelm","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1523096","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"T\u00fcreci","year":"2018","journal-title":"Oncoimmunology"},{"issue":"23","key":"10.1016\/j.biopha.2023.115717_bib50","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib51","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1038\/s41598-019-44874-0","article-title":"Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer","volume":"9","author":"Zhu","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2023.115717_bib52","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.amjsurg.2008.04.009","article-title":"Molecular targeted therapies for pancreatic cancer","volume":"196","author":"Borja-Cacho","year":"2008","journal-title":"Am. J. Surg."},{"issue":"5","key":"10.1016\/j.biopha.2023.115717_bib53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CJI.0b013e3182562d76","article-title":"Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation","volume":"35","author":"Luedke","year":"2012","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.biopha.2023.115717_bib54","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.amjsurg.2008.04.009","article-title":"Molecular targeted therapies for pancreatic cancer","volume":"196","author":"Borja-Cacho","year":"2008","journal-title":"Am. J. Surg."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(07)70383-2","article-title":"Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial","volume":"9","author":"Cascinu","year":"2008","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2023.115717_bib56","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115717_bib57","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41416-020-01046-6","article-title":"Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer","volume":"123","author":"Greene","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2023.115717_bib58","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1172\/JCI116001","article-title":"Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha","volume":"90","author":"Korc","year":"1992","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"KRAS mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115717_bib60","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211937120","article-title":"Multifaceted role for p53 in pancreatic cancer suppression","volume":"120","author":"Mello","year":"2023","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"key":"10.1016\/j.biopha.2023.115717_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.855474","article-title":"Pancreatic cancer: nucleic acid drug discovery and targeted therapy","volume":"10","author":"Dai","year":"2022","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2023.115717_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ctrv.2016.08.004","article-title":"RNA-targeted therapeutics in cancer clinical trials: Current status and future directions","volume":"50","author":"Barata","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2023.115717_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.101911","article-title":"Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance","volume":"46","author":"Papaefthymiou","year":"2022","journal-title":"Clin. Res Hepatol. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115717_bib64","first-page":"417","article-title":"Advances in modification and delivery of nucleic acid drugs","volume":"52","author":"Wang","year":"2023","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban."},{"key":"10.1016\/j.biopha.2023.115717_bib65","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2020.03.040","article-title":"Nucleic acid-based drug delivery strategies","volume":"323","author":"Tan","year":"2020","journal-title":"J. Control Release"},{"issue":"8","key":"10.1016\/j.biopha.2023.115717_bib66","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.ymthe.2021.06.010","article-title":"Aptamers: Cutting edge of cancer therapies","volume":"29","author":"Shigdar","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2023.115717_bib67","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.omtn.2017.11.013","article-title":"Targeted delivery of auristatin-modified toxins to pancreatic cancer using aptamers","volume":"10","author":"Kratschmer","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2023.115717_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.890614","article-title":"PAUF as a Target for Treatment of High PAUF-Expressing Ovarian Cancer","volume":"13","author":"Kim","year":"2022","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.115717_bib69","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s12276-021-00582-2","article-title":"Pancreatic cancer induces muscle wasting by promoting the release of pancreatic adenocarcinoma upregulated factor","volume":"53","author":"Yoo","year":"2021","journal-title":"Exp. Mol. Med"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib70","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1038\/s41598-018-30582-8","article-title":"Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer","volume":"8","author":"Choi","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib71","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2011.08.027","article-title":"An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells","volume":"313","author":"Kim","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.115717_bib72","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.omtn.2018.06.003","article-title":"Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer","volume":"12","author":"Park","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"20","key":"10.1016\/j.biopha.2023.115717_bib73","doi-asserted-by":"crossref","first-page":"10944","DOI":"10.3390\/ijms222010944","article-title":"Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer","volume":"22","author":"Yang","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-020-01237-y","article-title":"LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt\/\u03b2-catenin and autophagy pathway through modulating the miR-619-5p\/Pygo2 and miR-619-5p\/ATG14 axes","volume":"19","author":"Zhou","year":"2020","journal-title":"Mol. Cancer"},{"issue":"18","key":"10.1016\/j.biopha.2023.115717_bib75","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200143119","article-title":"Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer","volume":"119","author":"Principe","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib76","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drudis.2014.09.004","article-title":"Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer(\u00ae) therapeutics","volume":"20","author":"Vater","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2023.115717_bib77","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2023.115717_bib78","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/cmi.2017.107","article-title":"The unique structural and functional features of CXCL12","volume":"15","author":"Janssens","year":"2018","journal-title":"Cell Mol. Immunol."},{"issue":"17","key":"10.1016\/j.biopha.2023.115717_bib79","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","article-title":"Targeting CXCL12\/CXCR4 Axis in Tumor Immunotherapy","volume":"26","author":"Zhou","year":"2019","journal-title":"Curr. Med Chem."},{"issue":"50","key":"10.1016\/j.biopha.2023.115717_bib80","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.biopha.2023.115717_bib81","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib82","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41598-019-41251-9","article-title":"RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy","volume":"9","author":"Yoo","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib83","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.115717_bib84","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib85","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/21691401.2019.1608219","article-title":"Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA","volume":"47","author":"Chen","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"21","key":"10.1016\/j.biopha.2023.115717_bib86","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.3390\/molecules27217232","article-title":"Peptide-drug conjugates: a new hope for cancer management","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.biopha.2023.115717_bib87","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2174\/1568009621666211118111506","article-title":"Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management","volume":"22","author":"Malviya","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"issue":"9","key":"10.1016\/j.biopha.2023.115717_bib88","article-title":"Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting","volume":"101","author":"Mejia","year":"2022","journal-title":"Med. (Baltim. )"},{"issue":"18","key":"10.1016\/j.biopha.2023.115717_bib89","first-page":"5139","article-title":"Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo","volume":"62","author":"Zitzmann","year":"2002","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.biopha.2023.115717_bib90","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1021\/mp3002733","article-title":"RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis","volume":"9","author":"Danhier","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2023.115717_bib91","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2147\/DDDT.S366558","article-title":"A Novel Delivery System of RGD-HSA Loaded GEM\/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy","volume":"16","author":"Ma","year":"2022","journal-title":"Drug Des. Devel Ther."},{"issue":"6","key":"10.1016\/j.biopha.2023.115717_bib92","first-page":"2002147","article-title":"Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"7","key":"10.1016\/j.biopha.2023.115717_bib93","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/cas.15377","article-title":"Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs","volume":"113","author":"Milano","year":"2022","journal-title":"Cancer Sci."},{"issue":"5\u20136","key":"10.1016\/j.biopha.2023.115717_bib94","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/1061186X.2017.1419360","article-title":"Lipid-coated calcium phosphate nanoparticle and beyond: a versatile platform for drug delivery","volume":"26","author":"Huang","year":"2018","journal-title":"J. Drug Target"},{"issue":"3","key":"10.1016\/j.biopha.2023.115717_bib95","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ymthe.2018.11.012","article-title":"Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer","volume":"27","author":"Das","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2023.115717_bib96","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.colsurfb.2018.10.069","article-title":"PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy","volume":"174","author":"Ray","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biopha.2023.115717_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120546","article-title":"Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment","volume":"268","author":"Zhou","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2023.115717_bib98","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jconrel.2020.12.039","article-title":"Exosome-based photoacoustic imaging guided photodynamic and immunotherapy for the treatment of pancreatic cancer","volume":"330","author":"Jang","year":"2021","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib99","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1021\/acs.nanolett.9b04012","article-title":"Sheddable prodrug vesicles combating adaptive immune resistance for improved photodynamic immunotherapy of cancer","volume":"20","author":"Gao","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.biopha.2023.115717_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119845","article-title":"Photodynamic therapy produces enhanced efficacy of antitumor immunotherapy by simultaneously inducing intratumoral release of sorafenib","volume":"240","author":"Sun","year":"2020","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biopha.2023.115717_bib101","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1038\/s41467-019-11269-8","article-title":"Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223015159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223015159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:35:45Z","timestamp":1779917745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223015159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":101,"alternative-id":["S0753332223015159"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115717","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in targeted therapy for pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115717"}}